Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. GLMD.NASDAQ

Galmed Pharmaceuticals Ltd (GLMD NASDAQ) stock market data APIs

$0.297 -0.02(-6.4%) as of July 26, 2024
Price chart is built with Anychart

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Galmed Pharmaceuticals Ltd Financial Data Overview

0.3139
0.297
-
0.3169
0.297
0.26-1.2099
1 958 K
6 359 K
0
-0.98
0.69
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GLMD',
Type: 'Common Stock',
Name: 'Galmed Pharmaceuticals Ltd',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG005ZD02W1',
ISIN: 'IL0011313900',
CUSIP: 'M47238106',
CIK: NULL,
EmployerIdNumber: '98-1147233',
FiscalYearEnd: 'December',
IPODate: '2014-03-13',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

Galmed Pharmaceuticals Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -6 859 000
  • Earnings Per Share -1.65
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Galmed Pharmaceuticals Ltd Earnings via APIs

  • Latest Release 2024-05-30
  • EPS/Forecast -0.32

Get Galmed Pharmaceuticals Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Galmed Pharmaceuticals Ltd latest news via APIs

10 Oversold Global Stocks To Buy

In this piece, we will take a look at ten oversold global stocks to buy. If you want to skip our analysis of the global economic climate, then take a look at 5 Oversold Global Stocks To Buy. Like Jul...

Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada

Endo International plc’s ENDP wholly owned subsidiary, Endo Ventures Limited, has entered into an agreement with Quoin Pharmaceuticals Inc. QNRX for the development, supply, commercialization and di...
  • ENDO INTERNATIONAL
  • GALMED PHARMACEUTICALS
  • NETHERTON SYNDROME
  • ZACKS INVESTMENT RESEARCH
Do you have any questions?
support@eodhistoricaldata.com